Records containing: Triple Negative Breast Cancer

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2025-02-27
CMP-001 in Combination with Pre-Operative Stereotactic Body Radiation Therapy in Patients with Early Stage Triple Negative Breast Cancer: an Open-Label, Window of Opportunity, Randomized Phase 2 Clinical Study
CLINICAL_TRIALS study record update · 2025-02-21
NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
CLINICAL_TRIALS study record update · 2025-02-12
Efficacy of Intralesional IL-2 for Resectable Triple Negative Breast Cancer
CLINICAL_TRIALS study record update · 2025-02-10
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
CLINICAL_TRIALS study record update · 2025-01-29
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2025-01-23
A Randomized, Open Label, Parallel Controlled, Multicenter Phase II Clinical Study of Carelizumab Combined With TCb (Docetaxel+Carboplatin) Versus TCb Neoadjuvant Therapy for Triple Negative Breast Cancer
CLINICAL_TRIALS study record update · 2025-01-20
Routine MRI Screening Versus Symptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative and HER2+ Metastatic Breast Cancer (MBC): a Single-centre Randomized Pilot Study
CLINICAL_TRIALS study record update · 2025-01-17
A Phase 1a/1b Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjects With Advanced Solid Tumors.
CLINICAL_TRIALS study record update · 2025-01-16
A Single-Arm Phase II Trial of Neoadjuvant Toripalimab, Docetaxel, Plus Carboplatin in Patients With Localized Triple-Negative Breast Cancer
CLINICAL_TRIALS study record update · 2025-01-15
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
CLINICAL_TRIALS study record update · 2024-12-27
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
CLINICAL_TRIALS study record update · 2024-12-24
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
CLINICAL_TRIALS study record update · 2024-12-19
A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
CLINICAL_TRIALS study record update · 2024-12-09
Pilot Study of the Antibody-drug Conjugate Glembatumumab Vedotin (CDX-011) Following Doxorubicin (Adriamycin) and Cytoxan as Neo-adjuvant Therapy in Glycoprotein NMB-expressing High Risk Triple Negative Breast Cancer
CLINICAL_TRIALS study record update · 2024-12-03
OXEL: A Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy
CLINICAL_TRIALS study record update · 2024-11-25
A Cohort Study of Different Methods of Adjuvant Capecitabine Regimens in Patients With Non-PCR After Neoadjuvant Therapy for Triple Negative Breast Cancer
CLINICAL_TRIALS study record update · 2024-11-20
A Phase IB/II Study of Durvalumab (MEDI4736) Combined With Dose-dense EC in a Neoadjuvant Setting for Patients With Locally Advanced Luminal B HER2(-) or Triple Negative Breast Cancers.
CLINICAL_TRIALS study record update · 2024-11-20
De-escalation of Neoadjuvant Chemotherapy Regimens (Taxane Plus Carboplatin Versus Taxane Plus Carboplatin Sequential Anthracycline) With Immunotherapy Among TNBC
CLINICAL_TRIALS study record update · 2024-11-18
A Phase I Trial of the Combination of Olaparib and Navitoclax in Women with High Grade Serous Epithelial Ovarian Cancer and Triple Negative Breast Cancer
CLINICAL_TRIALS study record update · 2024-10-29
A Phase 1, Open-Label, Dose Finding Study of NI-1801, a Bispecific Mesothelin X CD47 Engaging Antibody, As a Single Agent, in Combination with Anti-PD-1 Antibody, and in Combination with Weekly Paclitaxel (Standard of Care) in Patients with Mesothelin Expressing Ovarian, Pancreatic, Non-Small-Cell-Lung and Triple-Negative Breast Cancers
CLINICAL_TRIALS study record update · 2024-10-17
Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies
CLINICAL_TRIALS study record update · 2024-10-15
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable Locally Advanced or Metastatic Cancer
CLINICAL_TRIALS study record update · 2024-10-15
ALICE: A Randomized Placebo-controlled Phase II Study Evaluating Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer
CLINICAL_TRIALS study record update · 2024-10-03
Vimentin Expression-based Therapeutic Response in Triple Negative Breast Cancer Receiving Combination of Simvastatin and NAC: a Randomized, Double-Blind, Placebo-Controlled Trial
CLINICAL_TRIALS study record update · 2024-09-25
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors